Please login to the form below

Zentiva

This page shows the latest Zentiva news and features for those working in and with pharma, biotech and healthcare.

Sanofi warns of difficult few months as diabetes sales slump

said that the last few months have included the pipeline-building acquisitions of Bioverativ and Ablynx and the sale of its Zentiva generics business to a private equity group.

Latest news

Sanofi appoints ex-Roche Reed as new R&D head

Brandicourt has also demonstrated his commitment to pursuing the core pharma business at Sanofi by selling off its Zentiva generics business for 1.9bn ($2.4bn).
Sanofi sells European generics to Advent for $2.4bn

Sanofi has been looking to divest the Zentiva generics unit since 2016 as part of restructuring the business under chief executive Olivier Brandicourt, who said: “Transferring this business to Advent is ... Sanofi bought the foundations of its European
Ten new medicines recommended in Europe

Duloxetine Zentiva (duloxetine) - a copycat of Lilly's Cymbalta - for the treatment of major depressive disorder, diabetic peripheral neuropathic pain and generalised anxiety disorder, also saw a nod from the EMA.
Three cancer immunotherapies amongst new CHMP approvals

Finally, two generic medicines gained positive opinions: Bortezomib Accord (bortezomib) for the treatment of multiple myeloma and mantle cell lymphoma and Pregabalin Zentiva (pregabalin) for the treatment of epilepsy and generalised
Orphan drugs in latest CHMP recommendations

Completing the positive opinions were two new informed consent applications: Sevelamer carbonate Zentiva (sevelamer) from Genzyme for the control of hyperphosphataemia in adults receiving haemodialysis or peritoneal dialysis and Rasagiline

More from news
Approximately 1 fully matching, plus 16 partially matching documents found.

Latest appointments

Karim Husny moves from Omega Pharma to Alliance Pharmaceuticals

He brings experience in over the counter and consumer healthcare having worked at several European pharmaceutical firms, including Laboratoire de la Mer, Pfizer and Sanofi's Zentiva business.
Watson selects global generics management team

Ramneborn has more than 20 years' experience in the pharmaceutical industry and joined Actavis from Zentiva, where he was vice president and a member of the board of directors since 2003.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Account Manager – Healthcare advertising: Salary TBC

Events Executive: DOE

Account Director – UK Office: Excellent salary and benefits

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Senior Medical Writer: Competitive salary plus benefits

Client Services Director- Flexible Working: Negotiable

Subscribe to our email news alerts

PMHub

Add my company

Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Report: Customer experience, shaping digital healthcare: In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Encouraging signs in biomarker R&D: The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it: What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...